Celebration, Fla-based KemPharm Inc, a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, recently updated its prodrug development pipeline. KemPharm is investigating “KP1077” as a potential treatment for idiopathic hypersomnia (IH), a sleep disorder of excessive sleepiness.

Travis C. Mickle, PhD, president and CEO of KemPharm, says in a release, “We continue to expand our pipeline with new growth opportunities for the company. In this regard, we are pleased to announce the discovery of our newest prodrug candidate, KP1077.”

[RELATED: FDA Fast Tracks Xywav for Idiopathic Hypersomnia]

It leverages KemPharm’s proprietary LAT (ligand activated therapy) technology, which the company utilizes to generate improved prodrug versions of US Food and Drug Administration (FDA)-approved drugs as well as to generate prodrug versions of existing compounds that may have applications for new disease indications.

Mickle adds that KP1077 may qualify for both Fast-Track status and Orphan Drug designation from the FDA.